PBAC's latest decision on Epcoritamab: Recommended with restriction (2024). Considered for Treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy, who have previously received or are currently unable to receive CAR-T cell therapy, and who are not eligible for stem cell transplantation.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Redacted
commercial-in-confidence
Submissions
1
first 2024
Submissions
1
2024 → 2024
Eligible population
Patients with relapsed or refractory DLBCL after two or more lines of systemic therapy who have previously received or are currently unable to receive CAR-T cell therapy and are not eligible for stem cell transplantation
Therapy area
Haematology
Line of therapy
Later-line
Evidence base
Single-arm
Primary endpoint
ORR
Key trials
EPCORE NHL-1, EPCORE DLBCL-1
Comparator
R-GemOx (rituximab + gemcitabine + oxaliplatin)
Economic model
CEA
ICER note
ICER not stated in public summary document; pricing details and economic model marked as redacted in submission
Risk sharing
Risk-sharing arrangement in place — Special pricing arrangements apply; effective prices redacted in the document